Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Clinical evidence

BOND

17 evidence topics · 2 sources

Objective
Location and study date
Registered study dates and sites
FieldQuoted record
Study start“2014-03”
Primary completion (actual)“2016-06”
Number of sites“This study has 7 locations”
Study chair“Alex W Yeung, MBBS”
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using complete response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
FieldQuoted record
Enrollment (actual)“22”
Description of analysis sets

No evidence found.

Results
Participant disposition
Study termination
FieldQuoted record
Reason for stopping“Change in study design”
Study completion (actual)“2016-06”
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations of BOND
  • BOND was registered as an integrated phase 2/3, open-label, randomized study of CG0070 against investigator choice of mitomycin C, interferon, valrubicin, or gemcitabine in participants with CIS-containing disease after BCG.
  • The registry lists the study as terminated for a “Change in study design” with 22 participants enrolled, from March 2014 to June 2016.
  • No results posted on ClinicalTrials.gov and no publication or company report of its efficacy or safety results were identified, so the study contributes no efficacy or safety data to this report.
  • Eligibility allowed participants who had been “successfully treated with BCG, but subsequently found to have recurrence”, so the registered population differs from the BCG-unresponsive population of BOND-003.